lidocaine and Bladder Pain Syndrome

lidocaine has been researched along with Bladder Pain Syndrome in 32 studies

Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.

Research

Studies (32)

Authors

Clinical Trials (12)

Trial Overview

Trial Outcomes

Change From Baseline in Daily Average Bladder Pain to Treatment 1 Week 4 Follow-up

The participant recorded their bladder pain over the previous 24-hour period in a 7-day pain assessment tool using an 11-point Numeric Rating Scale (NRS) (0 to 10) where 0=no pain to 10= worst pain. Pain data recorded over the 7-day period were averaged. A negative change from Baseline indicates improvement. An Analysis of Covariance (ANCOVA) model with baseline value as a covariate and treatment group and stratification factors (age group: < 40 years or ≥ 40 years and baseline bladder pain NRS: ≤ 6 or > 6) as factors was used for analysis. (NCT02411110)
Timeframe: Baseline (Days -7 to 0) to Treatment 1 Week 4

Change From Baseline in the Daily Average Bladder Pain Numeric Rating Scale (NRS)

The participant recorded their daily bladder pain score over the previous 24-hour period on a 7-day pain assessment tool as measured by an NRS on an 11-point scale where 0=no pain to 10=worst pain imaginable. The daily pain scores over the 7-day period were averaged. A negative change from Baseline indicates improvement. An analysis of covariance (ANCOVA) model with Baseline value as a covariate and treatment group and stratification (baseline bladder pain NRS: ≤ 5 or > 5) as factors was used for analysis. (NCT02395042)
Timeframe: Baseline (Day -7 to Day 0) to Week 4

Change From Baseline in the Number of Hunner's Lesions

During each cystoscopy, the investigator counted the number of lesions visible while performing the bladder scan. A negative change from Baseline indicates improvement (less lesions). An ANCOVA model with Baseline value as a covariate and treatment group and stratification (baseline bladder pain NRS: ≤ 5 or > 5) as factors was used for analysis. (NCT02395042)
Timeframe: Baseline (Day 0) to Week 4

Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire

Total scores range: 0-36 (0= no symptoms to 36= the most severe symptoms) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported

Change From Baseline in Treatment Response as Measured by the Visual Analogue Scale (VAS) for Pain

VAS is measured on marking on a 10-centimeter (cm) ruler (measured in cm, 0= no pain and 10= most severe pain possible) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported

Number of Participants With at Least One Adverse Event

Adverse events will only be those determined to be related to the study drug (NCT03463915)
Timeframe: End of study (6 weeks)

Overactive Bladder Questionnaire (OAB-q)

Total scores range: 0-100 (higher scores on the symptom-severity scale suggestive of greater severity of symptoms and higher scores on the quality-of-life scale suggestive of better quality of life) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported

Pelvic Floor Distress Inventory (PFDI)

20 question self-administered questionnaire on the presence and absence of pelvic floor symptoms. Score ranges from 0 (least distress) to 300 (most distress). (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported

Pelvic Pain and Urgency/Frequency (PUF) Questionnaire

Total scores range: 0-35 (0= no symptoms to 35= the most severe symptoms) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported

Sexual Function Measured by the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) Questionnaire

Measures sexual function in women with pelvic floor disorders. Queries about arousal, orgasm, partner-related issues, sexual quality, and desire. The tool also takes into account those who are not sexually active. The questionnaire was used in the study solely to determine if patients had improved dyspareunia (as a categorical variable). (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported

Change in IC Symptom Index Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline

"To determine the change in interstitial cystitis symptom index at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline).~The IC symptom index questionnaire consists of 4 questions on IC symptoms. 2 of the questions have 6 answer choices ranging from 0-never, to 5-almost always. 1 question has 6 answer choices ranging from 0-never to 5-usually. 1 question has 7 answer choices ranging from 0-never to 6-5 or more times. The numerical score for each question are added together, with a minimum score of 0 and a maximum score of 21. A higher score indicates greater severity of IC symptoms." (NCT02517996)
Timeframe: Baseline, 2 weeks, 6 weeks, 3 months (Up to 3 months)

Change in Pain Level as Assessed by the Visual Analog Scale (VAS)

"To determine the change in pain at 2 hours, 2 weeks, 6 weeks, and 3 months postoperatively in patients undergoing hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline) using the visual analog scale (VAS).~VAS consists of a 10cm horizontal line with the minimum endpoint labeled no pain (0) and maximum labeled worst pain ever (10). Patients placed a mark on the point that corresponds to the level of pain severity they felt. The cm distance from the low end of the VAS to the patient's mark is used as the numerical index of the intensity of pain. Pain scores of 3.0-5.4 cm are moderate, over 5.4 indicates severe pain." (NCT02517996)
Timeframe: Baseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)

Change in Pelvic Urgency, Pain, and Frequency (PUF) Questionnaire With Preemptive Pudendal Nerve Block Compared to Saline

"To determine the change in pelvic urgency, pain and frequency (PUF) questionnaire at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline).~The Pelvic Urgency, Pain, and Frequency Patient Symptom Scale asks 11 questions, 7 on PUF symptoms, 4 on how bothersome PUF symptoms are. Symptom questions include 3, 4, or 5 ranked answers, with higher answers indicating more voids, or greater frequency of pain. The bother questions each of 4 ranked answers from 0-never, to 3-always. The symptom score is added, the bother score is added, and then the total score is added. The total PUF score is then reported. The minimum score is 0 and the maximum score is 35, and a higher score indicates greater symptoms and higher bother from pelvic pain and frequency." (NCT02517996)
Timeframe: Baseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)

Change in Problem Index (O'Leary Sant) With Preemptive Pudendal Nerve Block Compared to Saline

"To determine the change in problem index (O'Leary Sant) at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline).~The IC problem index questionnaire consists of 4 questions on how much of a problem a patient's IC symptoms cause them. Each question has 5 answer choices ranging from 0-no problem, to 4-big problem. The numerical score for each question are added together, with a minimum score of 0 and a maximum score of 16. A higher score indicates that IC symptoms cause more problems for the patient." (NCT02517996)
Timeframe: Baseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)

Average Weekly NRS for Frequency at 6 Weeks

NRS - numerical rating scale, 0-10 is the range, and higher scores are worse frequency (NCT00427648)
Timeframe: 6 weeks

Cystometric Assessment of Maximal Bladder Capacity at 6 Weeks Only.

This is based on retrograde infusion of sterile water into the bladder using a catheter, the maximum tolerated volume serving to define how much distension a woman can tolerate. (NCT00427648)
Timeframe: 6 weeks

Global Assessment of Change - Frequency at 6 Weeks

This is patient overall assessment of change in overactive bladder symptoms after treatment. 0% is no change, 100% is total resolution of symptoms (NCT00427648)
Timeframe: 6 weeks

Median Number of Daily Voiding Episodes (by 3-day Voiding Diary) at Six Weeks.

(NCT00427648)
Timeframe: 6 weeks

Median Number of Daily Voiding Episodes at 12 Months.

(NCT00427648)
Timeframe: 12 months

OAB-q (Symptom Scale) at 6 Weeks

OAB-q SS is a 7 item overactive bladder symptom bother sub scale, ranging from 0-100, higher scores mean worse outcome for bother (NCT00427648)
Timeframe: 6 weeks

SF-12 Physical at 6 Weeks

SF-12 physical is an abbreviated version of the SF-36 a widely used, general health care quality of life instrument. Scores range from 0-100, and higher scores are better outcomes. (NCT00427648)
Timeframe: 6 weeks

Reviews

7 reviews available for lidocaine and Bladder Pain Syndrome

Trials

12 trials available for lidocaine and Bladder Pain Syndrome

Other Studies

13 other studies available for lidocaine and Bladder Pain Syndrome